TriSalus Life Sciences (NASDAQ:TLSI) Receives “Buy” Rating from Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report released on Friday,Benzinga reports. The firm currently has a $11.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price for the company. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $11.79.

TriSalus Life Sciences Trading Up 0.4 %

TLSI opened at $5.18 on Friday. The stock has a 50-day moving average of $4.48 and a 200-day moving average of $4.77. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now directly owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 70,012 shares of company stock worth $281,235 over the last three months. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in TLSI. Walleye Capital LLC acquired a new position in TriSalus Life Sciences in the third quarter worth about $66,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the third quarter valued at $184,000. Finally, Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.